Photodermatitis from topical phenothiazines A case series
Claire Cariou, Catherine Droitcourt, Marie Noelle Osmont, Marie Claude Marguery, Hervé Dutartre, Juliette Delaunay, Martine Avenel-Audran, Alain Dupuy, Henri Adamski

To cite this version:
Claire Cariou, Catherine Droitcourt, Marie Noelle Osmont, Marie Claude Marguery, Hervé Dutartre, et al.. Photodermatitis from topical phenothiazines A case series. Contact Dermatitis, 2020, 83 (1), pp.19-24. 10.1111/cod.13509. hal-02534804

HAL Id: hal-02534804
https://univ-rennes.hal.science/hal-02534804
Submitted on 30 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Photodermatitis to topical phenothiazines: a case series

Claire Cariou 1; Catherine Droitcourt 1,2; Marie Noelle Osmont 3; Marie Claude Marguery 4; Hervé Dutartre 5; Juliette Delaunay 6; Martine Avenel-Audran 6; Alain Dupuy 1,2; Henri Adamski 1.

Affiliations:
1 Department of Dermatology, CHU Pontchaillou, Rennes, France
2 UPRES-EA-7449 REPERES, Rennes, France
3 Centre of Pharmacovigilance, CHU Pontchaillou, Rennes, France
4 Paul Sabatier University and Department of Dermatology, Larrey Hospital, Toulouse, France
5 Department of Dermatology, CHU Hotel Dieu, Nantes, France
6 Department of Dermatology, Angers University Hospital, Angers, France

Conflicts of interest: None to declare.
Correspondence:

Dr Henri Adamski, Department of Dermatology, CHU Pontchaillou, 2 rue Henri le Guilloux 35000 Rennes, France, Tel: 00 33 2 99 28 43 49, Fax: 00 33 2 99 28 41 00, E-mail : henri.adamski@chu-rennes.fr

SUMMARY

Background:

In Europe, contact photosensitivity to phenothiazines is known particularly in southern countries. Topical phenothiazines are widely used and sold over-the-counter for the treatment of mosquito bites and pruritus in France.

Objective:

To report a series of cases with photodermatitis to topical phenothiazines.

Method:

A retrospective study of cases of contact dermatitis to phenothiazines seen in French photodermatology centres was performed.

Results:

In all, 14 patients with the diagnosis of contact dermatitis to phenothiazines were included. These developed eczema on the application sites, and in 13 the eruption spread to photodistributed sites. Topical products containing isothipendyl were the most common cause of photodermatitis. One patient had photoaggravated eczema due to promethazine cream. All patients stopped using topical phenothiazines and were treated successfully with topical corticosteroids. One patient relapsed and developed persistent light eruption. In all of the 9 cases tested, photopatch testing to the topical phenothiazine used “as is” was positive. Isothipendyl, chlorproethazine and the excipients were not tested. Photopatch tests to chlorpromazine and promethazine were positive in 8/12 and 7/13 tested respectively.


Conclusion:

Use of isothipendyl and promethazine as over-the-counter (or even prescribed) drugs needs to be limited due to severe reactions and sensitization to other phenothiazines that otherwise will have to be avoided.

KEYWORDS

Photoallergic contact dermatitis, eczema, topical phenothiazines, isothipendyl, CAS no. 482-15-5, promethazine, CAS no. 60-87-7, photopatch test

1. INTRODUCTION

Photosensitivity is a potential adverse effect of systemic phenothiazines used as antipsychotic. Topical phenothiazines that have anti-histamine and muscle relaxant effects are widely prescribed and used as over-the-counter (OTC) antipruritic drugs. In Europe, topical photosensitivity to phenothiazines, notably to promethazine, is known particularly in southern countries. Neuriplege ointment responsible for generalized and photoaggravated contact dermatitis due to active ingredient chlorproethazine was withdrawn from the French market in 2007. Three topical products containing phenothiazine, isothipendyl (Apaisyl gel, Sedermyl cream) and promethazine (Phenergan cream) are registered, and currently sold OTC for the treatment of mosquito bites and pruritus in France. Isothipendyl and promethazine are also sold in other European countries. The marketing authorization holders for these products are mainly located in Western Europe. The objective of the present study was to address the question of photosensitive dermatitis to topical phenothiazines since 2007.

2. METHODS
A retrospective study of cases of contact dermatitis to phenothiazines seen in French photodermatology centres from January 1, 2007 to October 31, 2019 was performed. Patients with a clinical diagnosis of contact dermatitis to a topical phenothiazine were included.

All members of the French Society of Photodermatology (SFPD) from 21 different French photodermatology units were contacted to contribute their eligible patients. A standardized questionnaire was sent to the SFPD members. The following information was collected from patient medical records: age, sex, medical history, current medications, clinical features, results of skin tests and photobiological exploration if performed.

3. RESULTS

3.1 Patient characteristics

A total of 14 patients were diagnosed with contact dermatitis to topical phenothiazine between January 2007 and October 2019. There were 6 female and 8 male patients, with a mean age at the time of diagnosis of 62 years (range: 27-88). The clinical characteristics of the patients are shown in Table 1. Case 11 has been previously reported. Of the 14 patients, 3 had a history of photosensitive diseases. Case 3 had solar urticaria and cases 4 and 7 polymorphous light eruption. All developed eczema at the site of application of phenothiazine during sunny seasons. Distant sites were secondarily involved, including photodistributed areas, in 13 of 14 patients. The duration of eczema was longer than 3 months in 9/14, with recurrence in spring and summer (cases 3-5, 7 and 12). Topical product containing isothipendyl were the most common cause of photodermatitis (13/14). One patient used both isothipendyl gel and chlorproethazine ointment. Case 14 had photoaggravated eczema due to promethazine cream. Hospitalization was needed in cases 1, 2, 11 and 12. All patients stopped using topical phenothiazine and were treated successfully with a topical corticosteroid within 1 month. Relapse was observed in case 13 who developed persistent light eruption in the 2 years following contact photosensitization to isothipendyl, and needed to use photoprotective clothes and sunscreens. Other long-term medication was continued in all cases.
3.2 Photobiological investigations

Phototesting was performed on the back of patients using a solar simulator (Dermolum UM-UW, Müller Elektronik, Moosinning, Germany) equipped with a xenon light and metal halide lamp providing polychromatic irradiation (solar spectrum, 95% UVA/5% UVB) filtered with Schott WG 305 (cases 1, 3-5, 7-14) to evaluate minimal erythema dose (MED) at 24h after exposure. UVA MED and irradiation of patches were performed with UVA source: Waldmann (Reischtett, France) in cases 1, 3-5 and 12 (UV 182), case 6 (UV 801 KL) and cases 7-11 (UVA 700); and Dermolum (UM-UW, Müller Elektronik) with Schott WG 345 filter in cases 13 and 14. Photopatch tests included the SFPD standard series (29 photoallergens: antiseptics, cosmetics, plant products, promethazine, chlorpromazine and 8 UV filters)\(^6\) with an extended list (11 other UV filters, ketoprofen, methylisothiazolinone, decyl glucoside and patients’ own products). Patches were applied on the upper back in triplicate. One set was covered for 24 h and then irradiated with 5J/cm\(^2\) UVA and the other with polychromatic light (0.75 of the MED) whereas the third set was left in occlusion for 72h. Final readings were performed at 72h, according to International Contact Dermatitis Research Group guidelines.

Thirteen patients underwent photobiological explorations (Table 2). In all of the 9 cases tested, photopatch testing to the topical phenothiazine used “as is” was positive. Chlorproethazine, isothenidine and the excipients were not tested because these substances had not been readily available. Photopatch tests to chlorpromazine 0.1% pet. and promethazine 0.1% pet. were positive in 8/12 and 7/13 tested, respectively. In one patient, the patch test to promethazine was positive without photoaggravation. Case 13 had also photosensitization to mequitazine administered for the treatment of eczema. In addition, past or associated relevant contact sensitivity (Myroxylon pereirae, fragrance mix, methylisothiazolinone) was found in 6 patients. The MED (polychromatic spectrum and/or UVA) was decreased in 4 cases. Two patients had repeated assessment of their MEDs which was normal 3 months later in case 11. Concerning the patient with persistent light eruption
(case 13), polychromatic MED returned to normal value while UVA MED was still decreased after one year of follow-up.

4. DISCUSSION

In most of our cases, contact photodermatitis was due to the products containing isothipendyl. One patient had no photobiological work-up. Nevertheless, the diagnosis of photocontact dermatitis to phenothiazines was made because eczema started on light-exposed areas following use of isothipendyl gel without relapse after discontinuation of the drug. In the literature, two cases of contact dermatitis to isothipendyl have been previously reported, including one of our patients. In France, benefit-risk assessment of isothipendyl products was initiated in 2017. Based on data from the French pharmacovigilance database and isothipendyl marketing authorization holders, 20 cases of severe cutaneous adverse reactions were identified (rash, urticaria, photodermatosis, eczema and purpura). The benefit-risk balance of isothipendyl was considered unfavorable, but this drug is still marketed to date. In our series, 4 patients were hospitalized. We observed one case of persistent light reaction due to isothipendyl as previously reported to chlorproethazine. This patient cross-photoreacted to another phenothiazine (mequitazine). In photoallergic reactions, cross-reactions between molecules belonging to the same chemical class such as phenothiazines may occur. In our series, some positive photopatch tests with a + reaction to isothipendyl gel and promethazine may represent just a phototoxic reaction. However, we consider this result as photoallergy owing to prior eczema in the patients. Positive photopatch tests to chlorpromazine and/or promethazine confirmed isothipendyl photoallergy in most of our patients using Apaisyl or Sedermyl. Such cross-sensitivity renders phenothiazines contra-indicated in patients with photocontact dermatitis from isothipendyl, as previously reported in cases with contact sensitization to chlorproethazine (Fig. 1). Moreau et al reported their experience among 20 patients and showed that isothipendyl is potentially phototoxic with UVA exposure, and induces more reactions than promethazine. These results were confirmed by photophysical analysis. The only difference in the chemical structure between isothipendyl and
promethazine is the presence of nitrogen in isothipendyl, which may explain its higher photosensitizing potential.\textsuperscript{7} Contact photoallergy to isothypendyl was probably facilitated by the application of this topical drug on eczematous skin, promoting the penetration of the molecule and allergen presentation to immunocompetent cells. Regarding severe cutaneous drug reactions, 2 cases of toxic epidermal necrolysis after isothipendyl gel application has been reported.\textsuperscript{11}

Topical promethazine is known to cause contact dermatitis and photosensitivity.\textsuperscript{1-4,12} In our series, one patient had photoaggravated eczema due to promethazine cream as previously published.\textsuperscript{13} Goossens et al observed photoallergic reaction in 2 of 14 patients with contact allergy to topical promethazine among 12460 patch tests carried out.\textsuperscript{1} In addition to sensitization to promethazine, our patient had concomitant positive photoreaction to \textit{Myroxylon pereirae} (balsam of Peru) and fragrance mix which could be explained by the presence of lavender essential oil as excipient ingredient in Phenergan cream. In our cases of photosensitive eczema to isothipendyl, co-sensitization to \textit{Myroxylon pereirae}, fragrance mix and methylisothiazolinone was not due Apaisyl and Sedermyl in view of the absence of these allergens in isothipendyl products.

The present report confirms the need to keep chlorpromazine and promethazine in the photopatch test baseline series as a diagnostic marker of phenothiazine photoallergy according to the European Society for Contact Dermatitis and the European Society for Photodermatology recommendation.\textsuperscript{14} The photobiological explorations showed here that UVA is associated with phenothiazines photosensitivity, as in most drug-induced photosensitization.\textsuperscript{15} Some patients also reacted to UVB included in polychromatic spectrum irradiation.

In conclusion, we described a series of cases of contact photodermatitis to phenothiazines. In the most of the patients, eczema was due to products containing isothipendyl. Photocontact allergy to topical phenothiazines may be underestimated and lead to a delay in diagnosis, as in our series. Use of isothipendyl and promethazine needs to be limited due to severe reactions.
In case of dermatitis on uncovered areas, it is recommended to focus the patient’s history on topical products applied, and photopatch testing is recommended.

REFERENCES


9. ANSM, Agence nationale de sécurité du médicament et des produits de santé. Séance n°5 Commission de suivi du rapport entre les bénéfices et les risques des produits de santé - Compte rendu de la réunion du 3 octobre 2017. Available at:


**TABLES**

Table 1. Baseline and clinical characteristics of cases.

Table 2. Patch and phototest results.

**FIGURE**

Fig. 1. Phenothiazines chemical structures
<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Past medical history</th>
<th>Long term (over 6 months) concomitant medication</th>
<th>Topical phenothiazine used</th>
<th>Application and period of use</th>
<th>Location of eczema</th>
<th>Symptoms duration before diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>68</td>
<td>M</td>
<td>Hypertension, dyslipidemia</td>
<td>Verapamil, irbesartan, hydrochlorothiazide, atorvastatin</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous, 8 months</td>
<td>Face, neck and upper chest</td>
<td>7 months</td>
</tr>
<tr>
<td>2</td>
<td>87</td>
<td>M</td>
<td>Diabetes, dyslipidemia, hypertension</td>
<td>Glicazide, simvastatin, benazepril, hydrochlorothiazide, acetylsalicylate</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>15 days</td>
<td>Face, neck, upper chest, forearms then abdomen and thighs</td>
<td>7 days</td>
</tr>
<tr>
<td>3</td>
<td>43</td>
<td>F</td>
<td>Solar urticaria</td>
<td>Bilastine</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous, 2 years</td>
<td>Face, chest, forearms and dorsum of the hands</td>
<td>2 years</td>
</tr>
<tr>
<td>4</td>
<td>27</td>
<td>M</td>
<td>Polymorphous light eruption</td>
<td>Hydroxychloroquine</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 4 years</td>
<td>Face, neck and dorsum of the hands</td>
<td>4 years</td>
</tr>
<tr>
<td>5</td>
<td>39</td>
<td>F</td>
<td>Cholecystectomy</td>
<td>None</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 1 year</td>
<td>Face and upper chest</td>
<td>1 year</td>
</tr>
<tr>
<td>6</td>
<td>57</td>
<td>F</td>
<td>Hypothyroidism</td>
<td>Levothyroxine</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>3 days</td>
<td>Neck, shoulders, hand back</td>
<td>3 weeks</td>
</tr>
<tr>
<td>7</td>
<td>74</td>
<td>M</td>
<td>Polymorphous light eruption</td>
<td>Hydroxychloroquine</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 3 years</td>
<td>Face, neck, forearms</td>
<td>3 years</td>
</tr>
<tr>
<td>8</td>
<td>69</td>
<td>M</td>
<td>Diabetes, dyslipidemia, hypertension</td>
<td>Metformin, rosuvastatin, perindopril, diltiazem</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 5 years</td>
<td>Left upper limb</td>
<td>1 month</td>
</tr>
<tr>
<td>9</td>
<td>66</td>
<td>M</td>
<td>None</td>
<td>None</td>
<td>Apaisyl gel (isothipendyl), Neuriplege ointment (chlorproethazine)</td>
<td>7 days</td>
<td>Face, neck, forearms, dorsum of the hands</td>
<td>1 month</td>
</tr>
<tr>
<td>10</td>
<td>88</td>
<td>M</td>
<td>None</td>
<td>None</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 3 months</td>
<td>Thumbs, dorsum of the hands, neck, face then trunk and lower limbs</td>
<td>6 months</td>
</tr>
<tr>
<td>11</td>
<td>56</td>
<td>F</td>
<td>Venous insufficiency of legs</td>
<td>None</td>
<td>Apaisyl gel (isothipendyl)</td>
<td>Discontinuous 4 months</td>
<td>Face, forearms, dorsum of the hands</td>
<td>4 months</td>
</tr>
<tr>
<td>12</td>
<td>88</td>
<td>F</td>
<td>Dubreuilh melanoma, thyroidectomy</td>
<td>Levothyroxine</td>
<td>Sedermyl cream (isothipendyl)</td>
<td>Discontinuous 13 months</td>
<td>Face, forearms, upper chest</td>
<td>13 months</td>
</tr>
<tr>
<td>13</td>
<td>53</td>
<td>F</td>
<td>None</td>
<td>None</td>
<td>Sedermyl cream (isothipendyl)</td>
<td>1 day</td>
<td>Face, dorsum of the hands and feet</td>
<td>4 months</td>
</tr>
<tr>
<td>14</td>
<td>72</td>
<td>M</td>
<td>None</td>
<td>None</td>
<td>Phenergan cream (promethazine)</td>
<td>Discontinuous 1 month</td>
<td>Face, neck and back</td>
<td>1 month</td>
</tr>
</tbody>
</table>

### Table 2. Patch and phototest results

<table>
<thead>
<tr>
<th>Case</th>
<th>Polychromatic minimal erythema dose (J/cm²)</th>
<th>UVA minimal erythema dose (J/cm²)</th>
<th>Topical phenothiazine used as is NI/UVA/polychromatic (day 3)</th>
<th>Chlorpromazine 0.1% pet. NI/UVA/polychromatic (day 3)</th>
<th>Promethazine 0.1% pet. NI/UVA/polychromatic (day 3)</th>
<th>Other positive patch tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Decreased (&lt;0.5, N&gt;1)</td>
<td>ND</td>
<td>Apaisyl - /+++/ND</td>
<td>-/+/ND</td>
<td>-++++/ND</td>
<td>-/-/-</td>
</tr>
<tr>
<td>2†</td>
<td>ND</td>
<td>ND</td>
<td>Apaisyl ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3</td>
<td>Normal (1.25, N&gt;1)</td>
<td>ND</td>
<td>Apaisyl - /+++/ND</td>
<td>-/ND</td>
<td>-/+/ND</td>
<td>-/-/-</td>
</tr>
<tr>
<td>4</td>
<td>Normal (1.75, N&gt;1)</td>
<td>ND</td>
<td>Apaisyl ND</td>
<td>-++++/ND</td>
<td>-/-/ND</td>
<td>Methylisothiazolone 0.2% aq. ++++/++++/ND</td>
</tr>
<tr>
<td>5</td>
<td>ND</td>
<td>ND</td>
<td>Apaisyl ND</td>
<td>-/-/ND</td>
<td>-/+/ND</td>
<td>Myroxylon pereirae 25% pet. +/+</td>
</tr>
<tr>
<td>6</td>
<td>ND</td>
<td>ND</td>
<td>Apaisyl - /+++/ND</td>
<td>ND</td>
<td>-++/ ND</td>
<td>-/-/ND</td>
</tr>
<tr>
<td>7</td>
<td>Normal (0.42, N&gt;0.4)</td>
<td>Decreased (&lt;15)</td>
<td>Apaisyl -/+</td>
<td>-/-/-</td>
<td>-/-/-</td>
<td>-/-/-</td>
</tr>
<tr>
<td>8</td>
<td>Normal (0.7, N&gt;0.4)</td>
<td>Normal (&gt;15)</td>
<td>Apaisyl -/+</td>
<td>-/-/-</td>
<td>-/-/-</td>
<td>Myroxylon pereirae 25% pet. +/++++</td>
</tr>
<tr>
<td>9</td>
<td>Normal (1.55, N&gt;0.4)</td>
<td>Normal (&gt;15)</td>
<td>Neuriplege and Apaisyl ND</td>
<td>-++++/++++</td>
<td>-/-/-</td>
<td>-/-/-</td>
</tr>
<tr>
<td>10</td>
<td>Normal (1.88, N&gt;0.4)</td>
<td>Normal (&gt;15)</td>
<td>Apaisyl -/-/+</td>
<td>-++++/++++</td>
<td>-/-/-</td>
<td>-/-/-</td>
</tr>
<tr>
<td>11</td>
<td>Decreased (0.05, N&gt;0.4)</td>
<td>Decreased (&lt;15)</td>
<td>Apaisyl -/+</td>
<td>-/+/-</td>
<td>-/-/-</td>
<td>-/-/-</td>
</tr>
<tr>
<td>12</td>
<td>Decreased (&lt;0.5, N&gt;1)</td>
<td>ND</td>
<td>Sedermyl ND</td>
<td>-/+/-/ND</td>
<td>-/-/-/ND</td>
<td>Myroxylon pereirae 25% pet. +/+/ND</td>
</tr>
<tr>
<td>13</td>
<td>Decreased (&lt;0.5, N&gt;1)</td>
<td>Decreased (&lt;15)</td>
<td>Sedermyl +/++++/++</td>
<td>-/+/-/ND</td>
<td>-/-/-/ND</td>
<td>Mequitazine‡ +/++++ Fragrance mix 8% pet. -/+/-</td>
</tr>
<tr>
<td>14</td>
<td>Normal (1.6, N&gt;1)</td>
<td>Normal (&gt;15)</td>
<td>Phenergan +++++/+++</td>
<td>-/+/-/ND</td>
<td>+++++/+++</td>
<td>Myroxylon pereirae 25% pet. +/+/- Fragrance mix 8% pet. -/+/-</td>
</tr>
</tbody>
</table>

Abbreviations: N: normal value of polychromatic minimal erythema dose depending on center evaluation specified. NI: Non-irradiated. ND: not done. +, ++, +++: positive reaction, -: negative reaction at 72 hours (day 3) according to ICDRG (International Contact Dermatitis Research Group). † Case 2 declined photobiological explorations and did not relapse after 9 months of follow-up. ‡ Mequitazine pet. (contents of Primalan® tablet).